BACKGROUND: Data from longitudinal studies suggest that biomarkers of inflammation and endothelial dysfunction are associated with development of hypertension. None of these studies have examined the association of these markers with hypertension risk in persons with diabetes. We examined the associations of inflammatory and endothelial dysfunction markers with long-term hypertension incidence in persons with type 1 diabetes mellitus. METHODS: The 15-year cumulative incidence of hypertension was measured in Wisconsin Epidemiologic Study of Diabetic Retinopathy participants (n = 795). Hypertension was defined as a systolic blood pressure > or =140 mm Hg and/or a diastolic blood pressure > or =90 mm Hg and/or history of current antihypertensive treatment. We measured serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1, and serum total homocysteine as "novel" markers of hypertension development. The relation of risk factors to hypertension incidence was determined using a proportional hazards approach with discrete linear logistic regression modeling. RESULTS: After controlling for age, gender, diabetes duration, body mass index, glycosylated hemoglobin, baseline systolic and diastolic blood pressure, proteinuria, and chronic kidney disease status, sVCAM-1 was significantly related to higher odds of developing incident hypertension (odds ratio per log sVCAM-1 1.95, 95% CI 1.01-3.74). None of the other markers of inflammation and endothelial dysfunction were related to incident hypertension in the cohort. CONCLUSIONS: Our data showed that sVCAM-1 as a marker of endothelial dysfunction was the strongest predictor of hypertension risk in individuals with type 1 diabetes. This association was independent of the presence of diabetic nephropathy. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND: Data from longitudinal studies suggest that biomarkers of inflammation and endothelial dysfunction are associated with development of hypertension. None of these studies have examined the association of these markers with hypertension risk in persons with diabetes. We examined the associations of inflammatory and endothelial dysfunction markers with long-term hypertension incidence in persons with type 1 diabetes mellitus. METHODS: The 15-year cumulative incidence of hypertension was measured in Wisconsin Epidemiologic Study of Diabetic Retinopathyparticipants (n = 795). Hypertension was defined as a systolic blood pressure > or =140 mm Hg and/or a diastolic blood pressure > or =90 mm Hg and/or history of current antihypertensive treatment. We measured serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1, and serum total homocysteine as "novel" markers of hypertension development. The relation of risk factors to hypertension incidence was determined using a proportional hazards approach with discrete linear logistic regression modeling. RESULTS: After controlling for age, gender, diabetes duration, body mass index, glycosylated hemoglobin, baseline systolic and diastolic blood pressure, proteinuria, and chronic kidney disease status, sVCAM-1 was significantly related to higher odds of developing incident hypertension (odds ratio per log sVCAM-1 1.95, 95% CI 1.01-3.74). None of the other markers of inflammation and endothelial dysfunction were related to incident hypertension in the cohort. CONCLUSIONS: Our data showed that sVCAM-1 as a marker of endothelial dysfunction was the strongest predictor of hypertension risk in individuals with type 1 diabetes. This association was independent of the presence of diabetic nephropathy. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Arpita Basu; Alicia J Jenkins; Julie A Stoner; Suzanne R Thorpe; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Timothy J Lyons Journal: Atherosclerosis Date: 2014-07-15 Impact factor: 5.162
Authors: Yalcin Solak; Baris Afsar; Nosratola D Vaziri; Gamze Aslan; Can Ege Yalcin; Adrian Covic; Mehmet Kanbay Journal: Hypertens Res Date: 2016-04-07 Impact factor: 3.872
Authors: I Mateo-Gavira; F J Vílchez-López; M V García-Palacios; F Carral-San Laureano; F M Visiedo-García; M Aguilar-Diosdado Journal: J Hum Hypertens Date: 2016-08-18 Impact factor: 3.012
Authors: Howard D Sesso; Monik C Jiménez; Lu Wang; Paul M Ridker; Julie E Buring; J Michael Gaziano Journal: J Am Heart Assoc Date: 2015-09-21 Impact factor: 5.501
Authors: Ana M Blázquez-Medela; Omar García-Sánchez; Víctor Blanco-Gozalo; Yaremi Quiros; María J Montero; Carlos Martínez-Salgado; José M López-Novoa; Francisco J López-Hernández Journal: PLoS One Date: 2014-08-22 Impact factor: 3.240
Authors: Isabel Ferreira; Peter Hovind; Casper G Schalkwijk; Hans-Henrik Parving; Coen D A Stehouwer; Peter Rossing Journal: Diabetologia Date: 2017-11-03 Impact factor: 10.122